At a Glance
- Study Type: Study
- Condition: Premutation or full mutation Fragile X
- Age: 0–5
- Sex: All
- Participant: Child plus parent or caregiver
- Location: Home
- Travel Considerations: No travel required
- Sponsor: The John Merck Fund
We are currently enrolling children born in North Carolina.
RTI International and the University of North Carolina at Chapel Hill are conducting a research study to learn more about early development of young children with Fragile X in North Carolina, and the experiences of their parents when obtaining the diagnosis and early intervention services.
This research study is currently seeking male and female children that have a premutation or full mutation Fragile X (including mosaic) and meet the following criteria:
- Age 0–5.
- Born in North Carolina.
- Lived in North Carolina between the ages of 0 and 3 years.
- Live in a home where English is the primary language spoken.
What to Expect
Research study activities for qualified children and their parents include:
- Home Visits: Depending on the child’s age, there will be 1–3 home visits (developmental assessments) with you and your child, each taking 2–3 hours:
- At enrollment
- Age 3
- Age 5
- Summary Reports: After each visit, you will receive a brief summary report about your child’s development plus a $50 gift card for your time.
- Questionnaires: Parents will be asked to complete some questionnaires (approx. 1–2 hours).
The following is a list of some of the assessments and questionnaires that will be included in the study:
- Bayley-3/SB-5 (50 mins)
- PDMS-2 (30–45 mins)
- AOSI (up to 18 months) 20 mins/ADOS (45–60 mins)
Parent Report Questionnaires: Questionnaires will be sent ahead of time so that parents have plenty of time to complete.
- Vineland Adaptive Behavior Scales, Third Edition (20 mins)
- Sensory Profile, Second Edition (10–20 mins)
- Rothbart Temperament Very Short Forms (10 mins)
- Medical Outcomes Study-Social Support Survey (5 mins)
- Feeding Flock Assessment. (1–2 surveys, 10–20 mins)
- Sleep Questionnaire (5 mins)
- Family Demographics including FX status (5 mins, 1st visit only)
- Behavior Rating Inventory of Executive Function (BRIEF) (15 mins)
- State-Trait Anxiety Inventory (10 mins)
- Parenting Stress Index (PSI), Fourth Edition: Short Form (10 mins)
A Mom Shares Her and Her Son’s Experience Participating in a Fragile X Clinical Trial »
Diane and her son Joshua volunteered for a clinical trial a little over a year ago. In this heartwarming video, his mom shares how their family made the decision to participate, and what the experience has been like so far.
Dr. Elizabeth Berry-Kravis on the Challenges Inherent in a Clinical Trial »
We asked NFXF scientific advisor, doctor, and clinical researcher Dr. Elizabeth Berry-Kravis to comment on the challenges inherent in a clinical trial.
Clinical Trials From Start to Finish (Webinar) »
Sharyn Lincoln and Katherine Pawlowski of Boston Children’s Hospital speaks with us about how clinical research trials work, what it takes to participate, and what happens after the study.
Learn About Clinical Trials »
From ClinicalTrials.gov, maintained by the National Library of Medicine (NLM) at the National Institutes of Health (NIH).
Need More Information?
Our Most Recent Opportunities
The Research in Neurodevelopmental Disabilities Lab at the Waisman Center at the University of Wisconsin-Madison is looking for parents of male or female children 6 to 17 years old with Fragile X syndrome for an online survey.
RTI International and the University of North Carolina at Chapel Hill are conducting an early intervention study to learn about the best ways to support early development in infants identified with the full mutation of Fragile X. Babies 0–9 months old with the full mutation, and their caregivers, may be eligible to participate.
Doctors at Rush University are researching cognition, balance, and walking patterns in people who carry a premutation in the Fragile X (FMR1) gene.
The University of South Carolina is conducting a research study focusing on the range of language, social, and cognitive features that may be associated with variations on the FMR1 gene. Women age 35-75 who are carriers of the Fragile X premutation may be eligible to participate.